CAYSTON 75 MG
AZTREONAM : 75 MG · DIN 02329840 · GILEAD SCIENCES CANADA INC
Health Canada status: MARKETED
What is CAYSTON?
CAYSTON 75 MG contains AZTREONAM : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02329840, held by GILEAD SCIENCES CANADA INC, supplied as POWDER FOR SOLUTION for INHALATION administration. Health Canada currently lists it as marketed, status dated 18-May-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CAYSTON used for?
Management of cystic fibrosis (CF) patients with chronic pulmonary Pseudomonas aeruginosa infections. Not demonstrated in FEV1 <25% or >75% predicted.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02329840 |
|---|---|
| Brand name | CAYSTON |
| Generic / active ingredient | AZTREONAM : 75 MG |
| Manufacturer | GILEAD SCIENCES CANADA INC |
| Strength | 75 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | J01DF01 AZTREONAM |
| AHFS class | 08:12.07.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-May-2011 |
| Original market date | 2009-11-11 00:00:00 |
How is it administered?
75 mg reconstituted with 1 mL diluent, inhaled 3 times daily for 28 days, followed by 28 days off. Use a bronchodilator before each dose. Doses should be at least 4 hours apart.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Vials: Refrigerate at 2-8°C; room temperature (up to 25°C) for up to 28 days. Diluent: 15-30°C or refrigerated. Use immediately after reconstitution.
How is it supplied?
Each kit contains 84 sterile vials of CAYSTON and 88 sterile diluent ampules (two 14-day supply cartons).
Contraindications
Known allergy to aztreonam or to any ingredient in the formulation or any components of the container.
Warnings and precautions
Use only with Altera Nebulizer System. Risk of bronchospasm; use bronchodilator before dosing. Severe cutaneous adverse reactions (SCAR) reported. Potential cross-reactivity with beta-lactams.
Who else supplies AZTREONAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AZTREONAM appears in 12 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.